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Summary The DNA-binding fluorescent dye Hoechst 33342 (H33342) has been used in a series of
investigations of the vascular parameters of two murine tumours. This dye has been shown, to have a short
half-life in the circulation (T- less than 2min), but is stably bound for at least 2h after it enters cells. It can
be used in morphometric studies on frozen sections to determine the effective vascular volume, the capillary
fraction and the size distribution of blood vessels in each tumour. These latter two parameters cannot be
deduced from the less labour intensive techniques using radioactive isotopes.
The effective vascular volume perfused in 1 min by H33342 was compared with the volume perfused in
30min with 5"Cr labelled erythrocytes. Similar volumes were estimated with the two techniques in a murine
carcinoma and in a sarcoma. Both techniques showed that the vascular volume decreased in larger tumours.
The H33342 analysis of vessel size showed the decrease in capillary vessels in the carcinomas was even
greater, falling from 70% in small tumours to 20% in larger tumours. The deteriorating vascular network in
larger tumours is associated with an increasing fraction of necrotic tissue.
Experiments in which the isotopes and dye were co-injected suggest that at 40mgkg' the dye may rapidly
lead to a partial shutdown of the tumour vascular bed. This is less marked with 20mgkg-1. In spite of this
effect there is in general a close correlation between the volumes perfused by labelled red blood cells and the
fluorescent dye.
The growth of solid tumours depends on the tumour
vasculature and pattern of blood flow, as does the response
to most forms of cancer therapy. However, neovasculari-
zation is often inadequate, resulting in areas deprived of
nutrients and oxygen (Thomlinson & Gray, 1955; Tannock
1968). The regions of local tissue hypoxia are thought to be
one of the major determinants of tumour response to
radiation (Gray et al., 1953; Thomlinson & Craddock, 1967),
and limitations in blood circulation and drug delivery have
been implicated in the resistance of tumours to chemo-
therapy (Siemann, 1982). It is therefore important to under-
stand the processes and patterns of vascular development in
different tumour types. Over the years, vascular development
in tumours has been extensively studied using a variety of
techniques (for review see Peterson, 1978). These in-
vestigative methods can be broadly classified into two types:
(a) those which identify the total vascular bed, such as
histological stains applied to post-mortem samples and (b)
those techniques which identify only the perfused fraction of
the vasculature, such as radioisotopes.
Since the functioning microvasculature of an organ or
tumour at any moment may represent only part of the total
vascular bed, in vivo estimates of functional vascularity may
give a lower value than measures of the total vascular bed
(Tannock & Steel, 1969; Murray et al., 1987). This may be a
more meaningful index of the nutritional status of the tissue
than methods which identify the total vessel network,
although it is also important to know whether the non-
perfused vessels are temporarily or permanently closed.
Studies of functional circulation in tumours have been
mainly limited to radioisotope techniques using y-emitting
tracers; with these methods no direct histological assessment
of tissues and their vessel networks are made. This paper
describes a new in vivo technique, using a fluorescent DNA
stain- H33342, for the identification and quantitation of
functional vasculature from histological samples.
H33342 is a bisbenzimidazole dye which fluoresces
strongly under ultraviolet light. It rapidly diffuses into cells
and binds specifically and quantitatively to DNA (Arndt-
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Jovin & Jovin, 1977). Because of its low toxicity to viable
cells, H33342 is extensively used in flow cytometry studies
for cells labelled in vitro (Preisler, 1978; Durand & Olive,
1982). Its use as an in vivo marker has been suggested by
Reinhold and Visser (1983) and has been adopted by
Chaplin et al., 1985. Using tumours growing in 'sandwich'
observation chambers Reinhold and Visser observed by in
vivo trans-illumination that, following an intravenous in-
jection of H33342, cells lining the blood vessels were the first
to incorporate the drug. Chaplin et al. (1985) have subse-
quently used H33342 injections in vivo, in combination with
flow cytometry, and have documented large differences in
the fluorescence intensity between different cells in the
tumour population. They use these differences in drug
concentration to deduce the position of each cell relative to a
perfused vessel at the time of injection. Therefore, although
H33342 is not a specific stain of endothelial cells, its rapid
uptake into cells, and limited diffusibility across cell layers
may make it a useful compound for indentifying functional
vascular networks.
We have extended the technique described by Reinhold
and Visser (1983) to allow H33342-stained vessels to be
identified in histological samples. The vascular fraction and
profiles of vessel size have been quantitated in two different
experimental tumours over a range of tumour sizes. We have
compared the results with those obtained in the same tumour
types using the more conventional techniques of injecting
5"Cr-labelled red blood cells and 86RbCl to measure vascular
space and relative blood flow. In addition, by combining
H33342 injections with the isotope techniques, we have
investigated whether H33342 causes any perturbations in the
vascular parameters assessed using these tracers. The
pharmacokinetics of the drug in vivo, and the stability of
H33342 binding in cells are also discussed.
Materials and methods
Two different tumour types were used in this study, CaNT,
which is a moderately differentiated adenocarcinoma, and
SaF, which is a more rapidly growing anaplastic sarcoma.
Both tumours arose spontaneously and have been main-
tained by serial passage for more than 10 years. They have
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previously been extensively used in both radiation and
hyperthermia studies (Hill & Denekamp, 1979; Hill et al.,
1983). For the present experiments, tumour cell suspensions
were prepared by crudely mincing donor tumours and 12-16
week old CBA/Gy f BSVS mice were injected with 0.05ml
tumour brei s.c. on the rear dorsum. Prior to treatment,
tumours were measured 2-3 times weekly with calipers, and
were selected for treatment over a chosen range of volumes
between 2 and 1,000 mm3 (i.e. 1.5-12.5mm diameter).
Hoechst 33342 estimates ofvascular volume
H33342 was obtained from Aldrich Chemicals Ltd
(Gillingham, England). Solutions were made up in sterile
saline immediately before use. Mice were injected i.v. via one
of the lateral tail veins with 0.01 ml g of a 2 or 4mgml 1
solution (equivalent to doses of 20 or 40mgkg-1). These
doses are well below the toxic limits for this drug (LD50 in
mice 300mgkg-1, Olive et al., 1985) and were chosen as
they allowed easy identification of labelled cells in
histological sections. Mice were killed 1 min after injection,
and the tumours were dissected out and frozen in liquid
nitrogen. They were then stored at -70°C until they were
sectioned. For each tumour sample, 6pm cryostat sections
were cut at three different levels between one pole and the
equatorial plane. The sections were air dried and then
studied under ultraviolet illumination using a Leitz
microscope equipped with an epifluorescent source
(magnification x400).
Blood vessel outlines were identified by the surrounding
halo of fluorescent H33342-labelled cells (Figure 1). The
vascular volume fraction enclosed by these haloes was
measured using a point scoring system based on that de-
scribed by Chalkley (1943). Briefly, a graticule with a
random array of 25 points was focused on an area of the
section, and points falling inside rings of fluorescent cells
were scored as positive (see Figure 1). This procedure was
repeated over different areas of the tissue until a minimum
of 3,000 points in total had been accumulated from sections
cut at the three different levels. This sample size was chosen
to give a relative standard errort of approximately 10% on
the measured volume fractions (see footnote). The vascular
volume fraction* for each sample was calculated as the ratio
of positive to total points.
Two intravenously injected isotopes were also used to
Figure 1 CaNT tumour removed 1mmn after i.v. injection 01
20mgkg-1 H33342. Vessels are identified by the surrounding
fluorescent cells and the black lines drawn on to three of the
vessels indicate the space which would be scored as vascular.
measure vascular parameters. The vascular space perfused in
30min was measured by 51Cr labelled erythrocytes and the
functional perfusion in one minute measured from the 86Rb
extraction. Each isotope can be used alone, or if the two
isotopes are injected at different times they can be combined
to give two independent measurements in each mouse.
51Cr-Red blood cell estimates ofvascular volume
51Cr-labelled red blood cells were prepared using a method
similar to that described by Song and Levitt (1970). Five
millilitre freshly collected CBA blood was spun at 1,500rpm
for 10min, the plasma removed and the red cells incubated
for 30min with 100pCiNa2 51CrO4ml- 1 whole blood. The
cells were then spun down, the supernatant removed and
sterile PBS added to bring the volume back to 5ml. The
blood was then spun again and the procedure repeated twice
more to remove any unbound isotope. After the final
washing, the red cells were resuspended in sterile 2%
dextrose citrate and PBS (ratio 1:7). Mice were injected i.v.
with 0.1 ml of the 5'Cr-labelled blood and killed 30min
later. A blood sample was then obtained from the thorax
and the tumour was removed. All samples were weighed and
counted in a Wallac 1282 compu-gamma counter for
1,000sec or as long as was needed to accumulate 5,000
counts.
The vascular volume of the tumours was calculated as:
vascular volue (%) Ix5'Cr activity/g tumour vasclarvolme () =100X 5Cr activity/g blood
86RbCl extraction estimates ofvascular perfusion
Vascular perfusion relative to the cardiac output was
measured using the 86Rb extraction technique (Sapirstein,
1958). Mice were injected i.v. with 5pCi 86RbCl and killed
1 min later. The tumours and tail were then removed and the
weighted samples counted as described above. The 86Rb
counts per gram of tumour were expressed as a percentage
of the injected activity (minus residual activity in the tail
resulting from leakage at the injection site).
Influence ofHoechst 33342 on thefunctional vascular volume
or vascular perfusion
To determine whether injection of H33342 causes any
measurable changes in the patterns of blood flow in
tumours, an experiment was designed in which H33342 was
added to the second injection (i.e. was combined with the
86Rb Cl) to give a dose of 20 or 40mgkg-1. Thirty minutes
prior to sacrifice the 5'Cr RBCs were injected i.v., and
29min later 5yCi 86RbCl in PBS, or in a 2 or 4mgml-1
solution of H33342, was also given i.v. The mice were
sacrificed 1 min later and blood and tumour samples were
counted simultaneously for 86Rb and 5'Cr content. The
overlap of energies in the spectrum was determined in
reference samples and a simple correction applied to the
counts.
Hoechst 33342 measurements ofvessel diameter
The distributions of vessel sizes were determined in tumours
labelled with H33342. The diameters of vessels which had
been cut in transverse section (i.e. in which the lumen
identified by H33342 was approximately circular) were
measured using a calibrated graticule. The average of two
perpendicular diameters was determined for each vessel and
at least 100 vessels' diameters were measured for each
tumour.
*Volume fraction
V(%) =No of positive points (n)
Total points
tRelative standard error= /( ) x 100 -,In
Measurements ofnecrotic volume
To correct for differences in the proportion of tumour that is
viable in tumours of differing sizes, the proportion of
necrotic tissue was estimated in each tumour type for a
range of tumour sizes. The tumours were fixed in 10%TUMOUR VASCULATURE 249
formol saline, processed, sectioned at three different levels
and stained with H&E. The pattern of cell death was
usually one of large necrotic regions rather than of in-
dividual pyknosed cells. The samples were scored using the
system of point scoring described previously.
Hoechst 33342 pharmacokinetics
(A) The removal of H33342 from the blood following
intravenous injection was determined using a method similar
to that described by Olive et al. (1985). Blood was collected
from the hearts of mice at various times between 0 and
45min after injection, precipitated in ethanol (1/20 dilution)
and centrifuged at 4,000rpm for 10min. Samples of
supernatant were analysed for fluorescence on a Perkin-
Elmer luminescence spectrometer with excitation at 343nm
and emission readings taken at 478nm. The absolute levels
of H33342 were then determined by reference to a calibra-
tion curve.
(B) Estimates of the 'visible' duration of drug exposure
following injection of H33342 were obtained by the
histological assessment of tumour samples. Mice were in-
jected intravenously with 20 or 40mgkg-1 H33342 while the
blood supply to 100mm3 CaNT tumours implanted on the
back was occluded with a D-shaped clamp. The clamp was
then removed at varying intervals (between 1 and 60min
after injection) to allow blood and any remaining drug to
reperfuse the tumour vascular bed. One minute after re-
moving the clamp, the animal was killed and the tumour
removed for sectioning as described above. A scoring system
was used to estimate the fluorescence intensity in arbitrary
units (range 0-5).
Stability ofHoechst 33342 binding to cells in vivo
The proportion of tumour and stromal cells incorporating
H33342 and the stability of the bound compound in vivo
were measured in SaF tumours using an Ortho Cytofluoro-
graph. Tumours were removed 1 to 180min after a single
dose of 20mgkg-1 H33342 and dissociated into single cells
by mincing with scissors and pipetting in PBS. The resulting
cell suspension was filtered through 35pm nylon mesh to
remove any remaining clumps of cells and then centrifuged
at 300g for 10min. The pellet was resuspended in cold PBS
and analysed immediately in an Ortho cytofluorograph system
50-H with dedicated 2150 computer. H33342 was excited
with a band of ultraviolet light between 357 and 364nm
from a 5Watt argon ion laser operating at 100mW.
Fluorescent emission was collected above 410nm. The
staining profiles of H33342-labelled tumour cells were
analysed after gating on the forward scatter signal to exclude
debris and normal tissue cells in the suspension. The propor-
tions of tumour cells with significant drug uptake were
determined by comparing the staining profiles of H33342-
labelled cells with those of untreated controls.
Results
The concentrations of H33342 remaining in the blood at
various times after i.v. injection are shown in Figure 2A. The
drug was removed very rapidly from the circulation with an
initial exponential decrease for both the doses tested, and a
half time of 2min. This agrees closely with the values
obtained by Olive et al. (1985). A slower second component
is detectable for the last 0.5% of the drug, with a TI of 1 h,
after the higher dose.
Figure 2B shows the results of the experiment in which
500mm3 CaNT tumours were clamped just before injection,
and the clamp was left on for varying periods before the
blood was allowed to reperfuse the tumour. The fluorescence
levels in H33342-labelled cells were scored using an arbitrary
scale. As with the spectroscopy measurements, the intensity
of the visible fluorescence decreased rapidly during the first
few minutes after injection, and by 30min very little fluores-
cence was detectable.
The stability of H33342 binding to cells in vivo was
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Figure 2 Pharmacokinetics of H33342 in plasma and its uptake
into tumour cells. The left hand panel shows the concentration of
the dye in the plasma by spectrophotometry at various times
after injecting 20 (0) or 40mgkg-1 (U). The right hand panel
shows that fluorescent tumour cells were obtained only from
animals in which the occlusive clamp to the tumour was removed
within a few minutes after the injection. By 15-30mins
insufficient dye was left in the circulation to label the tumour
during 1 min ofperfusion.
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Figure 3 The incorporation of H33342 into cells was assessed
by flow cytometry. The total fraction of cells in the population
with measurable H33342 and the proportion which were heavily
labelled are shown.
measured using flow cytometry. The proportions of
fluorescent cells, indicating H33342 incorporation, are
plotted as a function of time after injection in Figure 3. Two
categories of cells are shown (a) the proportion of cells in
the total population with fluorescence levels above back-
ground and (b) the smaller proportion of 'highly' fluorescent
cells, presumably those cells closest to the circulating dye.
Both populations increased over the first 15min after in-
jection. This corresponds to the time following injection
during which H33342 could be measured in the blood and
was shown in Figure 2 to be available for incorporation into
cells. From 15 to 180min after injection, the populations of
fluorescent cells in both categories remained constant.
Although redistribution of H33342 between cells could occur
during this time without a change in the total proportion of
labelled cells, it is probable that the fraction of highly
fluorescent cells would be affected. No changes were seen in
the number of cells in either population, which suggests that
once the drug is bound to DNA it is stable.
Figure 1 shows a photomicrograph of a tumour removed
min after perfusion with 20mgkg' H33342. The regions
that were perfused by the dye can be clearly visual-
ized by the halo of fluorescent cells that surrounds
each vessel. The lines that have been drawn around 3 vessels
indicate how the vascular space would be identified for
scoring. Vessels of differing diameter are shown, ranging
from 12pm to 80gm.
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The data obtained from morphometric analysis of such
sections are summarised in Figure 4. The upper panel shows
CaNT tumours at sizes varying from 2 to 1,000 mm3, and
the lower panel shows similar data for SaF. The squares are
for mice injected with 40mmkg-1 and the circles for
20mgkg-1. There is no significant difference in the values
obtained with the 2 doses.
In the carcinoma there seems to be a gradual trend
towards lower values at higher sizes, falling from a vascular
volume of 4% at 2mm3, to --2.5% at 1,OOOmm3. In the
sarcoma the data are more scattered and are consistent with
a plateau at 2.8% for sizes up to 100 mm3, followed by a
progressive fall to - 1% at 1,000mm3.
It was clear from scanning of the sections that larger
tumours also showed more overt necrosis. This was
quantified for each tumour type from fixed sections stained
with H&E and is shown in Figure 5. The upper panel shows
that in CaNT tumours there was virtually no necrosis up to
20mm3, but it rose dramatically to 35% between 100 and
800mm3. The sarcoma (lower panel) showed 10% necrosis,
even at very small sizes, and this rose to 50% in the larger
tumours.
The necrotic proportion might reasonably be expected to
coincide with areas that are poorly perfused, and therefore in
order to relate the vascular tree to the viable tissue it is
supporting we have corrected each data point in Figure 4 by
the average necrotic fraction for that size of tumour to
obtain the percent of the viable tumour mass that is occupied
by perfused functional vessels. This is shown in Figure 6.
The low estimates of vascular volume at large sizes are most
influenced and the data more nearly fit a straight line at
about 3 +0.5% for both tumours. The scatter of the data for
SaF remains greater than that for CaNT.
Figure 7 shows the comparison of H33342 estimates of
vascular volume and those obtained from the 51Cr labelled
red blood cells. Data from both types of tumour are shown,
at sizes of 100 and 500mm3. For CaNT tumours (closed
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Figure 4 Vascular volume identified by a one minute ex-
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Figure 5 Necrotic fraction as a function of tumour volume.
Each point represents the value for an individual tumour and
lines have been fitted to the data by eye.
symbols), there is no significant difference between the
estimates obtained with the morphometric or the isotope
technique. The estimates for SaF tumours are less closely
matched, although neither technique gave consistently high
or low values.
Figure 8 shows the double labelling experiment in which
the two isotope measurements used alone were compared
with values obtained when H33342 was combined with the
second injection. Again both tumours were studied at
100mm3 and at 500mm3. There were differences in the
amount of 51Cr detected in tumours which received H33342
29min later, although in general the differences are small.
The upper panel shows the 51Cr estimates of vascular
volume are similar in the groups given isotopes alone or
when the fluorescent dye was coinjected min before
sacrifice. The estimates are slightly lower for 5 of the 8
groups that received the dye than in corresponding control
groups, but 2 of the groups showed increased vascular
volumes. There is no significant trend. The lower panel
shows a bigger discrepancy and a much larger scatter on the
86Rb data. Mice given H33342 concurrently with the 86RbCl
seem to show a reduced perfusion of the tumour compared
with those receiving 86RbCl alone. This effect is most
marked in the well perfused small SaF tumours (open
squares) but the trend is apparent in many of the groups. It
appears to be more marked in the mice receiving 40mgkg-1
than in those receiving 20mgkg-1 H33342, and this implies
a dose dependent change in the vasculature.
Figure 9 shows the histograms of vessel diameter in these
two tumours at 10, 100 and 500mm3. A range of vessel
diameters from <12.5 pm to> 50pm were measured. The
large vessels will be less effective as a nutritive supply
because of their reduced surface area:volume ratio and this
may be a contributory cause of the higher proportion of
necrosis seen in larger tumours. If the vessels below 12.5pm
diameter are regarded as the main nutritive capillaries it is
possible to calculate the fraction of the total vessels stained J
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Figure 6 Vascular volume as a fraction of viable tumour mass
plotted against tumour volume. The dotted lines are reproduced
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Figure 8 Effect of H33342 on the isotopic estimates of vascular
volume and perfusion. Upper panel: Vascular volume estimated
30min after injection of 51Cr-RBCs plotted against the same
parameter in mice co-injected with 20mgkg-1 (circles) or
40mgkg-1 (squares) H33342 one minute before removing the
tumours. Each point is the mean of 4-8 mice (±1 s.e.). Lower
panel: Relative perfusion measured by 1 min exposure to 86RbCl
against values obtained if H33342 was co-injected. SaF:open
symbols. CaNT-closed symbols.
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Figure 7 Vascular volume measured by a 30min exposure to
5'Cr-RBCs compared to the values obtained by a one minute
exposure to H33342. Data for 2 H33342 doses are shown -
20mgkg-1 (circles) and 40mgkg-1 (squares). SaF-open
symbols. CaNT-closed symbols.
with H33342 that forms the nutritive capillary bed. This is
illustrated in Figure 10. The panels show that 70% of the
vessels fall in this category for very small CA NT tumours,
falling to 20% at 800mm3. By contrast there is little size
dependency in SAF, with -35% of the vessels being small
in calibre at all sizes.
Discussion
The rapid uptake and stable incorporation of the fluorescent
dye H33342 have made it a useful marker in cell sorting
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Figure 9 Distribution of vessel sizes identified by 20mgkg 1
H33342. The combined data from a minimum of 4 tumours are
shown for 10, 100 and 500mm3 tumours. Upper panel: CaNT;
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studies (Arndt-Jovin & Jovin, 1977) and in vascular studies
of thin sandwich tumours that can be transilluminated in
vivo (Reinhold & Visser, 1983). Furthermore, the rapid
clearance of the drug from the circulation following injection
has been used by Chaplin et al. (1987) as part of a
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Figure 11 Capillary volume as a fraction of viable tumour mass
plotted against tumour size. Each point represents the value for
an individual tumour injected with a dose of 20 (0) or 40 (U)
mgkg-1 H33342.
fluorescent double labelling scheme to demonstrate that there
may be rapid opening and closing of vessels within tumours.
In the present study, we have compared H33342 estimates of
vascular morphometry with more conventional tracer
techniques, and have shown that it gives similar results to
51Cr-RBC's. However, we have also shown that it may cause
some decrease in the perfusion volume assessed by86RbCl if
they are co-injected, and in the vascular volume that is
identified by labelled red blood cells injected 29mins earlier.
The effect appears to be dose dependent. Since tumour
vasculature is generally passive this apparent vaso-
constriction may be due to a much smaller vasodilation in
the general circulation resulting from the bolus injection
directly into the tail vein.
Morphometric analyses and isotope techniques each have
their advantages and disadvantages. Whilst morphometry is
more labour intensive, it does allow the measured vascular
volumes to be analysed in terms of vessel size or in terms of
distribution across the tumour (i.e. architectural features can
be recognised). Care must be taken however to ensure that
the injected or infused marker is small enough to allow
access to all vessels and is stable enough to be retained in
situ throughout the processing of the sections. In these
respects H33342, with its rapid uptake into cells but poor
diffusion characteristics, is much superior to particulate
markers such as Indian ink, microspheres or photographic
emulsion gels. In comparison with many of the particulate
marker methods, in which vessels are perfused using ex-
ternally applied pressure, the H33342 technique relies simply
on the animals functioning circulation to distribute the drug
and consequently should provide a more accurate picture of
the normal patterns of blood flow. However, as shown by
our studies, it is important to assess the effect of any novel
injected substance on the normal vascular physiology or tone
by comparing the method against others already in use.
The isotope markers have the advantage of being less
labour intensive and more easily quantified, but they do not
readily allow architectural aspects of the vessel distribution
to be determined. Red blood cells may have difficulty in
access to the smallest capillaries, but they undoubtedly give a
reasonable approximation to the volume perfused by whole
blood in the 30min between injection and sacrifice. In this
study, for two different tumours, over a five-fold size range
the isotope and fluorescent dye techniques gave essentially
similar values. The suggests that the space perfused in1 min
is not much smaller than that perfused over a 30min period,
unless there is a fortuitous balance between the space
inaccessible to erythrocytes and the reduced vascular
perfusion that seems to accompany the H33342 injection.
Previously published values for vascular fractions in other
tumour systems are very varied depending on the techniques
used for identifying the vessel networks. In the studies
reported here, the vascular volume estimates in small
tumours were 3-4% but fell to 1-2% at larger sizes. These
values are similar to those quoted by Solesvik et al. (1982;
1985) for experimental mouse tumours and for xenografts of
human tumours growing in mice. In their studies, the
vascular system was filled with a radioopaque contrast
medium injected via the abdominal aorta.
The fall in vascular volume with tumour size has been
documented by other workers (Song & Levitt, 1971; Jirtle et
al., 1978) but this study shows that the proportion of viable
tumour mass that is perfused is less variable than the
proportion of the total tumour. This observation would
appear to support the belief that the development of overt
necrosis in larger tumours results from an imbalance
between the rates of proliferation of the vessel wall
components, inadequate branching of the new vessels and
gradual nutrient depletion in the longer vessel loops
(Peterson 1978; Denekamp & Hobson, 1982; Tannock, 1968;
Falk, 1978; Vaupel et al., 1981; Rubin & Casarett, 1966).
Although the estimates of vascular volume as a fraction of
the viable tumour mass remained roughly constant in both
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tumours over the size range measured, the tumours did show
individual characteristics in their vessel size distributions at
various sizes. In the adenocarcinoma, CaNT, increasing
tumour size was accompanied by an increase in larger
vessels. Therefore, although the vascular fraction was
maintained in larger tumours, it may disguise a decrease in
the proportion of nutritionally useful capillaries. If the
functional capillary volume is expressed as a fraction of the
viable tumour tissue it falls from almost 3% in small CaNT
tumours, to about 0.5% in large CaNT tumours (Figure 11).
This implies that the cells are metabolically less active in
large tumours, that the blood flow is more efficient, or that
it is inappropriate to consider small vessels as the only
nutritionally useful component of the vasculature. In the
sarcoma the fraction of viable tissue occupied by the capil-
lary space was between 1 and 2%, with no obvious size
dependence.
In conclusion, the fluorescent dye H33342 allows a more
detailed study of the vascular patterns in tumours than is
possible with isotopic methods. Although it may have a
slight effect on vessel tone, it gives estimates of the vascular
volume perfused at 1min that are closely similar to those
obtained from a 30min perfusion of labelled red blood cells.
It is shown to be a stable cell marker which has a rapid
clearance from the blood stream, and hence may be suitable
for studies in which multiple injections are used to measure
changes in vascular space as time is allowed for opening and
closing of vessels.
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